NCT06094426View on ClinicalTrials.gov

Autologous Tumor Infiltrating Lymphocyte Injection for the Treatment of Advanced Solid Tumors

EARLY_PHASE1RecruitingINTERVENTIONAL

Enrollment

36

Participants

Timeline

Start Date

February 26, 2023

Primary Completion Date

February 26, 2026

Study Completion Date

February 26, 2026

Conditions

Solid TumorAdultGT316

Interventions

BIOLOGICAL

GT316

Autologous Tumor Infiltrating Lymphocyte Injection

Trial Locations (1)

Unknown

RECRUITING

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

Sponsors

Lead Sponsor

Grit Biotechnology

All Listed Sponsors

lead

Grit Biotechnology

INDUSTRY